Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

5825 - First Report of Real-World Patient Characteristics and Treatment Patterns From POLARIS: Palbociclib in Hormone Receptor‒Positive (HR+) Advanced Breast Cancer – A Prospective, Multicenter, Noninterventional Study

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Topics

Targeted Therapy

Tumour Site

Breast Cancer

Presenters

Joanne Blum

Citation

Annals of Oncology (2018) 29 (suppl_8): viii90-viii121. 10.1093/annonc/mdy272

Authors

J.L. Blum1, S.L. McCune2, M.A. Salkeni3, D.M. Anderson4, J.J. Migas5, S. Lakhanpal6, K. Patel7, A. Bardia8, G. Rocque9, J. Wang10, J.C. Cappelleri11, G. Comstock12, Y. Wang13, D. Tripathy14

Author affiliations

  • 1 Medical Oncology, Texas Oncology, Baylor-Sammons Cancer Center, US Oncology, 75246 - Dallas/US
  • 2 Hematology/oncology, Northwest Georgia Oncology Centers, Marietta/US
  • 3 Hematology/oncology, West Virginia University Cancer Institute, Morgantown/US
  • 4 Hematology, Oncology And Transplantation, Health Partners Institute, St Paul/US
  • 5 Hematology/oncology, OSF St. Joseph Medical Center, Bloomington/US
  • 6 Hematology/oncology, Saint Vincent’s Birmingham, Birmingham/US
  • 7 Medical Oncology And Hematology, CARTI Cancer Center, Little Rock/US
  • 8 Harvard Medical School, Massachusetts General Hospital Cancer Center, Boston/US
  • 9 Hematology And Oncology, University of Alabama at Birmingham, Birmingham/US
  • 10 Biostatistics, Cytel Inc, Waltham/US
  • 11 Biostatistics, Pfizer Inc, Groton/US
  • 12 Breast Cancer, Oncology, Pfizer Inc, Santa Rosa/US
  • 13 Oncology Clinical Development And Medical Affairs, Pfizer Inc, New York/US
  • 14 Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston/US
More

Resources

Abstract 5825

Background

This study describes real-world use and population characteristics in HR+/HER2- advanced breast cancer (ABC) patients receiving palbociclib (PAL) in routine practice.

Methods

This prospective, noninterventional study has a targeted enrollment of 1500 men and women from ∼110 sites. Site and patient data, monitored remotely for clarity/completeness, are collected from medical charts, physician surveys, and patient-reported outcomes; optional blood samples are collected during standard-of-care lab draws.

Results

This is an interim report of the first 312 patients with completed baseline case report forms as of 9Mar18 from 66 US sites (data snapshot: 9Apr18). Most sites were community sites (79%) with 1-10 treating physicians (61%). Of 33 sites that use clinical pathways, 45% were based on NCCN and 42% on US Oncology guidelines. Selected patient characteristics are shown (Table). Before starting PAL at enrollment, 18% of patients received chemotherapy, 21% hormonal therapy, 11% radiotherapy, 4% surgical resection, and 66% had no prior ABC therapy. Overall, 72% of patients received PAL combination first-line, of whom 56% received PAL+letrozole or anastrozole, 41% PAL+fulvestrant, and 4% PAL+exemestane. Of patients receiving ≥second-line PAL, 46% received prior hormonal monotherapy, 43% prior chemotherapy alone, and 6% both.Table: 344P

Selected patient demographic and clinical characteristics

All Patients (N = 312)
Age at study enrollment, y
Median (range)63 (29-92)
Distribution, n (%)
<4012 (3.8)
40-5040 (12.8)
51-69156 (50.0)
70-7441 (13.1)
75-8451 (16.3)
≥8512 (3.8)
Sex, n (%)
Women308 (98.7)
Men4 (1.3)
Race, n (%)
White256 (82.1)
Black or African American46 (14.7)
Other7 (2.2)
Not reported3 (1.0)
Hispanic/Latino ethnicity, n (%)31 (9.9)
Insurance provider, n (%)
Private insurance152 (48.7)
Medicare133 (42.6)
Medicaid14 (4.5)
Uninsured5 (1.6)
Pre/perimenopausal, n (%)40 (12.8)
Distribution of disease-free interval, mo,* n (%)
<1297 (31.6)
12-<2411 (3.6)
24-<3625 (8.1)
≥36174 (56.7)
Number of present comorbidities by system organ class, median (minimum-maximum)4 (0-27)
Musculoskeletal and connective tissue disorders, n (%)245 (78.5)
Gastrointestinal disorders, n (%)225 (72.1)
Metabolism and nutrition disorders, n (%)190 (60.9)
Cardiac disorders, n (%)49 (15.7)
*

Disease-free interval was defined as the time from first diagnosis of breast cancer to onset of advanced/metastatic disease among patients with available initial breast cancer diagnosis dates and available date of first ABC diagnosis.

Conclusions

This is the first large, prospective multicenter study assessing real-world use of a CDK4/6 inhibitor. In the first 312-patient cohort, most were treated at community sites. A heterogeneous real-world population received PAL, including elderly, premenopausal, African-American, Latino/Hispanic, and male patients not commonly represented in clinical trials. Hormone partners received with PAL included steroidal and nonsteroidal aromatase inhibitors or fulvestrant, predominantly first-line.

Clinical trial identification

NCT03280303.

Legal entity responsible for the study

Pfizer Inc.

Funding

Pfizer Inc.

Editorial Acknowledgement

Editorial support was provided by Anny Wu, PharmD, of Complete Healthcare Communications, LLC (West Chester, PA), a CHC Group company, and funded by Pfizer Inc.

Disclosure

J.L. Blum: Steering committee: Pfizer Inc. M.A. Salkeni: Contracted research funding as study PI via author’s institution: West Virginia University. J.J. Migas, J. Wang: Contracted research: Pfizer Inc. A. Bardia: Advisory board: Novartis, Pfizer Inc, Spectrum Pharma. G. Rocque: Steering committee: Pfizer Inc; Contracted research: Genentech, Carevive, Pack Health, Medscape. J.C. Cappelleri, G. Comstock, Y. Wang: Employee and stockholder: Pfizer Inc. D. Tripathy: Steering committee: Novartis, Pfizer Inc; Contracted research: Novartis, Pfizer Inc. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.